Pomotrelvir
Based on 1 publication(s) in Google Scholar
Pomotrelvir is a selective, competitive, orally active covalent inhibitor of the SARS-CoV-2 main protease (Mpro), with an IC50 of 24 nM for wild-type SARS-CoV-2 Mpro. Pomotrelvir inhibits viral polyprotein processing, thereby preventing viral replication. Pomotrelvir has shown broad antiviral activity against multiple SARS-CoV-2 variants (including Omicron) in cell-based experiments, and has an additive effect when combined with nucleoside analogs that target viral RNA synthesis. Pomotrelvir is primarily used for the research and development of COVID-19 antiviral drugs, especially for infections caused by SARS-CoV-2 and its variants.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 96.73%
- CAS No.: 2713437-86-4
- 화학식: C23H26ClN5O3
- 분자량:455.94
-
보관:
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications Citing Use of MedChemExpress (MCE) Pomotrelvir
More
Biological Activity
|
SARS-CoV-2 (Mpro 24 nM (IC50) |
Enzyme activity assay:
Pomotrelvir competitively inhibits SARS-CoV-2 Mpro with a Ki of 2.7 nM; it also inhibits the Mpro of other human coronaviruses (CoV-229E, CoV-OC43, etc.) with an IC50 of 61-379 nM[1].
Cell infection assay:
Pomotrelvir (23-36 nM; 48 h) significantly inhibits viral replication in SARS-CoV-2 infection or replication experiments in iPS-AT2, A549-hACE2 and Huh7 cells with an EC50 value of 23-36 nM, and is effective against clinical isolates such as Omicron[1].
Cross-resistance experiment:
Pomotrelvir significantly reduces its inhibitory activity against Mpro carrying Nirmatrelvir (HY-138687) resistance mutations (such as E166V, H172Y), while some mutations (such as L50F, T21I) does not affect its inhibitory effect[1].
Binding specificity experiment:
Pomotrelvir (100 μM) had no inhibitory effect on caspase-2, Chymotrypsin C, etc. in the human protease inhibition experiment, showing high selectivity for SARS-CoV-2 Mpro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2713437-86-4
-
Appearance Solid
-
분자량 455.94
-
화학식 C23H26ClN5O3
-
Color White to off-white
-
SMILES
ClC1=C2C(C=C(N2)C(N[C@H](C(N[C@H](C#N)C[C@H]3C(NCCC3)=O)=O)CC4CC4)=O)=CC=C1
-
Synonyms
PBI-0451
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Antiviral Res
2025 Aug:240:106212. PMID: 40505777
용액&용해도
DMSO : 100 mg/mL (219.33 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
순도&문서
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Tong X, et al. Evaluation of in vitro antiviral activity of SARS-CoV-2 Mpro inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0084023. [Content Brief]
[2]. Schillings J, et al. Pomotrelvir and Nirmatrelvir Binding and Reactivity with SARS-CoV-2 Main Protease: Implications for Resistance Mechanisms from Computations. Angew Chem Int Ed Engl. 2024 Oct 1;63(40):e202409527. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1933 mL | 10.9664 mL | 21.9327 mL | 54.8318 mL |
| 5 mM | 0.4387 mL | 2.1933 mL | 4.3865 mL | 10.9664 mL | |
| 10 mM | 0.2193 mL | 1.0966 mL | 2.1933 mL | 5.4832 mL | |
| 15 mM | 0.1462 mL | 0.7311 mL | 1.4622 mL | 3.6555 mL | |
| 20 mM | 0.1097 mL | 0.5483 mL | 1.0966 mL | 2.7416 mL | |
| 25 mM | 0.0877 mL | 0.4387 mL | 0.8773 mL | 2.1933 mL | |
| 30 mM | 0.0731 mL | 0.3655 mL | 0.7311 mL | 1.8277 mL | |
| 40 mM | 0.0548 mL | 0.2742 mL | 0.5483 mL | 1.3708 mL | |
| 50 mM | 0.0439 mL | 0.2193 mL | 0.4387 mL | 1.0966 mL | |
| 60 mM | 0.0366 mL | 0.1828 mL | 0.3655 mL | 0.9139 mL | |
| 80 mM | 0.0274 mL | 0.1371 mL | 0.2742 mL | 0.6854 mL | |
| 100 mM | 0.0219 mL | 0.1097 mL | 0.2193 mL | 0.5483 mL |